Key Highlights
- Adicet Bio appoints Dr. Lloyd Klickstein to its Board of Directors.
- Dr. Klickstein brings over two decades of experience in biopharmaceutical leadership and research.
- His expertise will support Adicet’s mission in advancing gamma delta T cell therapies.
Source: Business Wire
Notable Quotes
- “We are pleased to welcome Dr. Klickstein to our Board of Directors. Dr. Klickstein’s expertise in rheumatology and immunology, proven track record in drug development and his scientific knowledge of our gamma delta T cell platform.” — Chen Schor, President and Chief Executive Officer at Adicet Bio
- “Leveraging its proprietary gamma delta T cell platform, Adicet has the potential to develop groundbreaking therapies for autoimmune and oncology indications.” — Dr. Lloyd Klickstein, President and Chief Executive Officer at Koslapp Therapeutics, Inc
SoHC's Take
Dr. Lloyd Klickstein’s appointment to Adicet Bio’s Board of Directors marks a significant enhancement to the company’s leadership. With his extensive background in immunology, rheumatology, and drug development, Dr. Klickstein’s expertise will be instrumental as Adicet continues to develop its innovative gamma delta T cell therapies. His previous roles, including his experience as a former executive at Adicet, position him uniquely to contribute valuable insights and drive forward the company’s mission of delivering cutting-edge treatments to patients.
